Infinity Pharmaceuticals
Naglaa Fikry is a seasoned professional with extensive experience in product management within the pharmaceutical industry. Currently serving as a Senior Product Manager at Infinity Pharmaceuticals since March 2018, Naglaa previously held product management roles at Delta Grand Pharma from December 2011 to May 2015, Western International Medical Guide for a brief period in 2010, and T3A Pharma from March 2006 to June 2009. Naglaa Fikry holds a Bachelor's degree in Biochemistry from Ain Shams University, obtained between 2000 and 2003, and attended Shoubra from 1998 to 2000.
This person is not in any offices
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies.